Order Now 1-800-246-8878

The end-to-end NGS solutions and onco-panels powered by the OptiSeq™ platform

OptiSeq™ NGS Targeted Sequencing Platform

No more costly and time-consuming deep sequencing! DiaCarta’s OptiSeq™ next-gen sequencing platform removes the cost and time barriers by reducing the sequencing depth by a factor of up to 100X and enabling ultra-sensitive detection of genetic mutations. The platform uses the XNA molecular clamp that only hybridizes the wild-type template. That way, only the mutant template is amplified and sequenced. 500 sequencing reads on the OptiSeq™ platform are equivalent to 50,000 reads without using the platform.

workflow

Features and benefits

Ultra-Sensitive

Ability to detect
≤0.1% mutations

Rapid

Whole process in
7-10 days

Accurate

Fewer errors by enriching mutant allele reads

Sample Ready

Suitable for FFPE tissue (e.g. solid tumor) and blood samples (e.g. ctDNA)

Reproducible

Robust XNA-PCR minimizes variability

Cost Effective

Achieve by reducing 100x read depth

Onco-panels

OptiSeq™ Actionable Panel (12 Genes)

ALKBRAFEGFRERBB2ERBB3ESR1KITKRASNRASPDGFRA
PIK3CARAF1

OptiSeq™ Lung Panel (15 Genes)

ALKBRAFEGFRERBB2ESR1IDH1IDH2KITKRASNRAS
RAF1PDGFRAPIK3CARETROS1

OptiSeq™ Prostate Panel (32 Genes)

AKAP9APCARCDK12CDKN1BCDKN2AGLI1IKZF4KDM4BKLF6
KMT2DMED12MYCNCOA2NIPA2NKX3-1NRCAMOR5L1PDZRN3PIK3CA
PTENRB1SCN11ASPOPSYNE3TBX20TFGTHSD7BTP53ZFHX3
ZNF473ZNF595

OptiSeq™ Colon Panel (38 Genes)

ACVR1BAKT1APCATMATP6V0D2BAXBRAFCASP8CDC27CTNNB1
DCCDMDEP300ERBB2FBXW7FZD3GPC6KRASMAP2K4MAP7
MIER3MLH1MSH2MSH3MSH6MYO1BNRASPIK3CAPIK3R1PTPN12
SLC9A9SMAD2SMAD4TCERG1TCF7L2TGFBR2TP53WBSCR17

OptiSeq™ Breast Panel (44 Genes)

ACVR1BAKT1ATMBAP1BRCA1BRCA2CBFBCDH1CDKN2AEGFR
EP300ERBB2ERBB3ESR1EXOC2EXT2FBXO32FGFR1FGFR2GATA3
IRAK4ITCHKMT2CMAP2K4MAP3K1MDM2MUC16MYCNCOR1NEK2
PBRM1PCGF2PIK3CAPIK3R1PPM1LPTENPTGFRRB1RETSEPT9
TP53TRAF5WEE1ZBED4

OptiSeq™ Target Panel (33 Genes)

ABL1AKT1ALKBRAFCTNNB1EGFRERBB2EZH2FBXW7FGFR1
FGFR2FLT3GNA11GNAQHRASIDH1IDH2JAK2KITKRAS
METMPLNOTCH1NPM1NRASPDGFRAPIK3CAPTENPTPN11RET
SMAD4SMOTP53

OptiSeq™ Pan-Cancer Panel (65 Genes)

ABL1AKT1ALKAPCATMBRAFBRCA1BRCA2CDH1CDKN2A
CSF1RCTNNB1DDR2DNMT3AEGFRERBB2ERBB3ERBB4EZH2FBXW7
FGFR1FGFR2FGFR3FLT3FOXL2GNA11GNAQGNASHNF1AHRAS
IDH1IDH2JAK2JAK3KDRKITKRASMAP2K1METMLH1
MPLMSH6MTORNF1NF2NOTCH1NPM1NRASPDGFRAPIK3CA
PIK3R1PTCH1PTENPTPN11RB1RETSMAD4SMARCB1SMOSRC
STK11TERTTP53TSC1VHL

OptiSeq™ Comprehensive Panel (76 Genes)

ABL1AKT1ALKASXL1BAALCBCORBCRBRAFCBFBCEBPA
CRLF2CTNNB1DDR2DEKDNMT3AEGFRERBB2ERGETV6MECOM
EZH2FAM5CFGFR1FGFR2FLT3FBXW7GNA11GNAQHOXA9HRAS
IDH1IDH2JAK2KITKRASMAP2K1METMKL1MLLMLLT3
MN1MPLMYCMYH11NF1NOTCH1NPM1NRASNUP214PDGFRA
PHF6PIK3CAPMLPTENPTPN11RAD21RARARBM15RETRUNX1T1
RPN1RUNX1SF3B1SMAD4SMC1ASMC3SMOSRSF2STAG2TET2
TP53TSC1U2AF1U2AF2WT1ZRSR2

Supporting data

    Melting Profiles of PCR Amplicon

ngs-melting-v2.0

OptiSeq™ applies XNA-PCR to predominantly enrich the KRAS codon 12 mutant allele from a lung tumor sample, resulting in a pure mutant PCR amplicon as indicated by a single peak in the high-resolution melting profile (on the left). PCR for conventional NGS  however, obscures the mutant allelic signal in the profile (on the right).

Ultra Sensitive Detection of BRAF V600 Mutation

ngs-data-4

Ultra-sensitive detection of rare and actionable mutations is achieved without deep sequencing. OptiSeq™ rapidly, precisely and cost-effectively detects the BRAF V600E mutation from ctDNA in whole blood. Shown is the detection levels of 5%, 1% and 0.1% mutant DNA, respectively.

OptiSeq™: Background Noise Reduction

ngs-ctDNA-v3.0

  • Data from circulating tumor DNA mutation sites
  • High background noise from wild-type DNA (filled and open circle below dotted line) separated from mutant DNA signal (inverted triangle above dotted line)